![]() Structural basis for inhibition of TSLP-signaling by Tezepelumab (PDB 5J13)
[1] | |
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | thymic stromal lymphopoietin (TSLP) |
Clinical data | |
Trade names | Tezspire |
Other names | MEDI9929, AMG 157, tezepelumab-ekko |
AHFS/ Drugs.com | Monograph |
License data |
|
Routes of administration | Subcutaneous |
Legal status | |
Legal status | |
Chemical and physical data | |
Formula | C6400H9844N1732O1992S52 |
Molar mass | 144590.40 g·mol−1 |
Tezepelumab, sold under the brand name Tezspire, is a medication used for the treatment of asthma. [3] [5] Specifically it is used for severe asthma, which is not controlled by other medication, in those at least 12 years old. [5] It is given by injection under the skin every 4 weeks. [5]
The most common side effects include joint pain and sore throat. [5] Other side effects may include allergic reactions. [3] While there is no evidence of harm in pregnancy, such use has not been well studied. [3] It is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), resulting in less airway inflammation. [3] [5]
Tezepelumab was approved for medical use in the United States in 2021 and Europe in 2022. [3] [5] In the United States it costs about 48,000 USD per year as of 2022. [6] While approved in the UK it was not yet marketed as of 2022. [6]
![]() Structural basis for inhibition of TSLP-signaling by Tezepelumab (PDB 5J13)
[1] | |
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | thymic stromal lymphopoietin (TSLP) |
Clinical data | |
Trade names | Tezspire |
Other names | MEDI9929, AMG 157, tezepelumab-ekko |
AHFS/ Drugs.com | Monograph |
License data |
|
Routes of administration | Subcutaneous |
Legal status | |
Legal status | |
Chemical and physical data | |
Formula | C6400H9844N1732O1992S52 |
Molar mass | 144590.40 g·mol−1 |
Tezepelumab, sold under the brand name Tezspire, is a medication used for the treatment of asthma. [3] [5] Specifically it is used for severe asthma, which is not controlled by other medication, in those at least 12 years old. [5] It is given by injection under the skin every 4 weeks. [5]
The most common side effects include joint pain and sore throat. [5] Other side effects may include allergic reactions. [3] While there is no evidence of harm in pregnancy, such use has not been well studied. [3] It is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), resulting in less airway inflammation. [3] [5]
Tezepelumab was approved for medical use in the United States in 2021 and Europe in 2022. [3] [5] In the United States it costs about 48,000 USD per year as of 2022. [6] While approved in the UK it was not yet marketed as of 2022. [6]